


Strengthening our presence with innovative pharmaceutical products

Pharmaceuticals revenue breakdown by region




Position in focus areas

Psychiatry & Neurology area (Global)

Sumitomo Pharma has established a leading position in the global market as the company continues to build a unique R&D pipeline in the psychiatric and neurological disorder therapeutic drug market, including atypical antipsychotic LATUDA®, which has global sales of approximately ¥200.0 billion.

Therapeutic drugs for Psychiatry & Neurology: Market share of pharma companies (2020)



Source: EvaluatePharma® 26 May 2022, © Evaluate Ltd. Excluding multiple sclerosis drug

North American market Psychiatry & Neurology area

LATUDA®

Revenue: **¥204.1 billion**

Indications Schizophrenia, Bipolar I depression



Features An atypical antipsychotic with antagonistic effects for dopamine D₂, serotonin 5-HT_{2A} and serotonin 5-HT₇ receptors and also acts as a partial agonist on serotonin 5-HT_{1A} receptors

About target disease

- Schizophrenia is a chronic disorder with various symptoms, including hallucinations, delusions, social withdrawal, decreased spontaneity, cognitive impairment, anxiety, and depression, that makes life, employment, and education difficult. The number of schizophrenia patients in the U.S. is approximately 2.4 million.
- Bipolar disorder is a chronic and serious disease characterized by repeated cycles of manic and depressive episodes. The main symptoms reported are depressed mood, loss of interest and joy, significant weight loss, insomnia, fatigue, feelings of worthlessness, decrease in ability to concentrate, and repeated suicide attempts. The number of schizophrenia patients in the U.S. is approximately 12.6 million.

APTiom®

Revenue: **¥27.1 billion**

Indications Partial-onset seizures (Monotherapy/Combination therapy)



Features APTiom® is a once-daily antiepileptic treatment FDA-approved for use as a monotherapy or adjunctive therapy for partial-onset seizures.

About target disease

- In the U.S., epilepsy is the fourth most prevalent neurological condition and approximately 2.9 million people are living with active epilepsy, including approximately 460,000 children aged 0 to 17 years.

KYNMOBI® Launched in September 2020

Revenue: **¥0.6 billion**

Indications OFF episodes in patients with Parkinson's disease



Features A sublingual film formulation of apomorphine, a dopamine agonist

About target disease

- Parkinson's disease is a chronic and progressive neurodegenerative disease characterized by motor and non-motor symptoms. By 2030, it is estimated that approximately 1.2 million people in the U.S. and 10 million people worldwide will be living with Parkinson's disease.
- OFF episodes are the worsening or re-emergence of motor and non-motor symptoms otherwise controlled with appropriate drug therapy. 40–60% of Parkinson's disease patients experience OFF episodes.

North American market Oncology and other areas

ORGOVYX® (relugolix* monotherapy)

Launched in January 2021

Revenue: **¥9.3 billion**

Indications Advanced prostate cancer



Features The first and only oral gonadotropin-releasing hormone (GnRH) receptor antagonist approved in the U.S.

About target disease

- Prostate cancer is the second most prevalent form of cancer in men and the second leading cause of death due to cancer in men in the U.S.
- More than 3 million men diagnosed with prostate cancer are alive in the U.S., and approximately 190,000 men were estimated to be newly diagnosed in 2020.

MYFEMBREE® (relugolix*, combination tablet)

Launched in June 2021

Revenue: **¥1.3 billion (includes RYEQO® sales)**

Indications Uterine fibroids



Features The first once-daily treatment approved in the U.S. for heavy menstrual bleeding associated with uterine fibroids in premenopausal women

About target disease

- An estimated 5 million women in the U.S. suffer from symptoms of uterine fibroids, and an estimated three million women are inadequately treated by current medical therapy and require further treatment.

*Relugolix is owned by Myovant Sciences Ltd. Sumitomo Pharma Group owns approximately 52% of the outstanding shares of Myovant.

GEMTESA® Launched in April 2021

Revenue: **¥7.1 billion**

Indications Overactive bladder (OAB)



Features First and only β₃-adrenergic receptor agonist in the U.S. with urgency data and no blood pressure warning in its label

About target disease


- Approximately over 30 million people in the U.S. suffer from bothersome symptoms of OAB, including urinary urgency, urge urinary incontinence, frequent urination, and nocturia which can have a significant impairment on a patient's day-to-day activities.

Diabetes area (Japan)

In addition to Equa®, a DPP-4 inhibitor, and EquMet®, a combination agent, Sumitomo Pharma has an extensive lineup of products which have different mechanisms of action, including Trulicity®, a GLP-1 receptor agonist, METGLUCO®, a biguanide, SUREPOST®, a glinide, GLIMICRON®, a sulfonylurea, and TWYMEEG®, a new product with a novel mechanism of action, securing a leading position for sales in Japan in this area.

*The sales collaboration for Trulicity® will conclude upon the expiration of the contract period on December 31, 2022.

Therapeutic drugs for diabetes: Market share of pharma companies (FY2021)



Japanese market Psychiatry & Neurology area

TRERIEF®

Revenue: **¥16.4 billion**

Indications Parkinson's disease, Parkinsonism in dementia with Lewy bodies



Features Parkinson's disease drug with levodopa-enhancing effect

About target disease

- The number of Parkinson's disease patients in Japan is approximately 160,000. Onset often affects those aged 50-65, with the rate of incidence increasing with age.
- Since no treatment currently exists for stopping the progression of the disease, appropriate pharmaceutical treatment or surgery is selected according to the severity of conditions.

LATUDA® Launched in June 2020

Revenue: **¥6.9 billion**

Indications Schizophrenia and bipolar depression



Features See North American market

About target disease

- Schizophrenia affects approximately 800,000 people in Japan.
- Bipolar disorder affects approximately 220,000 people in Japan.

LONASEN® Tape

Revenue: **¥2.1 billion**

Indications Schizophrenia



Features The world's first transdermal formulation approved for the indication of schizophrenia

About target disease

- See LATUDA® for Schizophrenia

Note: Revenue for the Japan market is fiscal 2021 performance results based on Invoice price.

Japanese market Diabetes area

Equa®/EquMet®

Revenue: **¥37.5 billion**

Indications Type 2 diabetes



Features Equa®: DPP-4 Inhibitor
EquMet®: A combination agent that includes DPP-4 Inhibitor and metformin

About target disease

- An estimated 10 million people in Japan have diabetes, with the majority of them having type 2 diabetes.
- Basic treatment is through exercise and dietary approaches; however, when blood glucose levels are not adequately managed, oral or injectable hypoglycemic agents are administered.

TWYMEEG®

Launched in September 2021

Revenue: **¥200 million**

Indications Type 2 diabetes



Features

- An oral hypoglycemic agent in a new class with a structure different from other such existing agents
- This drug may show a glucose lowering effect by both a pancreatic action that promotes glucose concentration-dependent insulin secretion and an extra-pancreatic action that improves glucose metabolism in the liver and skeletal muscle (suppression of gluconeogenesis and improvement of glucose uptake) through an action on mitochondria.

About target disease


- See Equa® and EquMet® for type 2 diabetes

Chinese market Infectious diseases

MEROPEN® (brand name in China: MEPEM®)

Revenue: **¥29.9 billion**

Indications General infections, febrile neutropenia



Features Standard therapy for severe infections, used in many countries